Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells

Blood (2011) 118 (21): 2736.

https://doi.org/10.1182/blood.V118.21.2736.2736

Published: 2011

Journal Articles

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

Emir Hadzijusufovic, DVM, Susanne Herndlhofer, Karl J. Aichberger, MD, PhD, Viviane Ghanim, M.D., Verena Suppan, BSc, Sabine Cerny-Reiterer, D.V.M., Wolfgang R Sperr, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 2753.

https://doi.org/10.1182/blood.V118.21.2753.2753

Published: 2011

Journal Articles

Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy

Wolfgang R. Sperr, MD, Otto Zach, PhD, Iris Poell, Michael Kundi, MD, Susanne Herndlhofer, Ulrich Jaeger, MD, Paul Knoebl, MD, Ansgar Weltermann, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 2504.

https://doi.org/10.1182/blood.V118.21.2504.2504

Published: 2011

Journal Articles

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,

Viviane Ghanim, M.D., Harald Herrmann, MD, Emir Hadzijusufovic, DVM, Barbara Peter, D.V.M., Katharina Blatt, M.Sc., Karina Schuch, Sabine Cerny-Reiterer, D.V.M., Irina Mirkina, PhD, Gerwin Heller, PhD, Sabine Zöchbauer-Müller, MD, Heidrun Karlic, PhD, Winfried F Pickl, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 3457.

https://doi.org/10.1182/blood.V118.21.3457.3457

Published: 2011

Journal Articles

5-Azacytidine and Decitabine Induce Demethylation and Re-Expression of FAS (CD95) and Promote Apoptosis in Neoplastic Cells in Acute Myeloid Leukemia (AML),

Heidrun Karlic, PhD, Rene Reitermaier, Viviane Ghanim, MD, Harald Herrmann, MD, Roman Thaler, M.Sc. PhD, Silvia Spitzer, Franz Varga, PhD, Irina Sadovnik, M.Sc., Katharina Blatt, M.Sc., Felix Keil, MD, Peter Valent, M.D., Michael Pfeilstöcker, MD

Blood (2011) 118 (21): 3463.

https://doi.org/10.1182/blood.V118.21.3463.3463

Published: 2011

Journal Articles

Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML,

Harald Herrmann, M.D., Katharina Blatt, M.Sc., Junwei Shi, Amy R. Rappaport, Karoline V. Gleixner, M.D., Sabine Cerny-Reiterer, D.V.M., Barbara Peter, D.V.M., Eric Wang, Wolfgang R. Sperr, M.D., James E. Bradner, MD, Scott W. Lowe, Ph.D., Christopher R. Vakoc, M.D., Ph.D., Johannes Zuber, M.D., Peter Valent, M.D.

Blood (2011) 118 (21): 3484.

https://doi.org/10.1182/blood.V118.21.3484.3484

Published: 2011

Journal Articles

Ponatinib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis,

Karoline V. Gleixner, M.D., Katharina Blatt, M.Sc., Barbara Peter, D.V.M., Emir Hadzijusufovic, DVM, Peter Valent, M.D.

Blood (2011) 118 (21): 3497.

https://doi.org/10.1182/blood.V118.21.3497.3497

Published: 2011

Journal Articles

The Leukemic Stem Cell (LSC) in Ph + CML Is a CD34 + /CD38 − /Lin − Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

Harald Herrmann, M.D., Irina Sadovnik, M.Sc., Sabine Cerny-Reiterer, D.V.M., Katharina Blatt, M.Sc., Viviane Ghanim, M.D., Susanne Herndlhofer, Gregor Hoermann, M.D., Thomas Rülicke, D.V.M., Michael Willmann, D.V.M., Gerlinde Mitterbauer-Hohendanner, M.D., Matthias Mayerhofer, M.D., Wolfgang R. Sperr, M.D., Peter Valent, M.D.

Blood (2011) 118 (21): 961.

https://doi.org/10.1182/blood.V118.21.961.961

Published: 2011

Journal Articles

The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release

Barbara Peter, D.V.M., Katharina Blatt, M.Sc., Gabriele Stefanzl, Emir Hadzijusufovic, DVM, Catherine Dutreix, Stefan H Gross, Johannes L Roesel, Peter Valent, M.D.

Blood (2011) 118 (21): 1417.

https://doi.org/10.1182/blood.V118.21.1417.1417

Published: 2011

Journal Articles

The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML

Karoline V. Gleixner, M.D., Harald Herrmann, M.D., Katharina Blatt, M.Sc., Winfried F Pickl, MD, Marina Konopleva, MD, PhD, Gahininath Y Bharate, Michael Andreeff, M.D., Ph.D., Hiroshi Maeda, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 4414.

https://doi.org/10.1182/blood.V118.21.4414.4414

Published: 2011

Journal Articles

Expression of the CAMPATH-1 Antigen (CD52) on CD34+/CD38- Progenitor Cells in Patients with 5q- MDS and in a Subset of AML

Katharina Blatt, M.Sc., Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Susanne Herndlhofer, Wolfgang R. Sperr, M.D., Peter Valent, M.D.

Blood (2011) 118 (21): 1728.

https://doi.org/10.1182/blood.V118.21.1728.1728

Published: 2011

Journal Articles

Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?

Blood (2010) 116 (21): 4008.

https://doi.org/10.1182/blood.V116.21.4008.4008

Published: 2010

Journal Articles

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.

Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Karoline V. Gleixner, M.D., Katharina Blatt, M.Sc., Susanne Herndlhofer, Hermine Agis, M.D., Werner Rabitsch, M.D., Berthold Streubel, M.D., Gerlinde Mitterbauer-Hohendanner, M.D., Wolfgang R. Sperr, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2010) 116 (21): 3382.

https://doi.org/10.1182/blood.V116.21.3382.3382

Published: 2010

Journal Articles

Identification of Novel Surface Markers and Targets In Neoplastic Stem Cells In AML and CML: a Flow-Gene-Flow Screen Approach.

Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Irina Sadovnik, M.Sc., Viviane Winter, M.D., Katharina Blatt, M.Sc., Werner Rabitsch, M.D., Wolfgang R. Sperr, M.D., Elena De Angelis, Ph.D., Steve Holmes, Ph.D., Peter Valent, M.D.

Blood (2010) 116 (21): 1575.

https://doi.org/10.1182/blood.V116.21.1575.1575

Published: 2010

Journal Articles

Establishment of a Novel Canine Mastocytoma Cell Line, NI-1: a Model for Studying Resistance Against KIT Tyrosine Kinase Inhibitors In Canine Neoplastic Mast Cells

Emir Hadzijusufovic, Barbara Peter, Harald Herrmann, Karina Schuch, Tuddow Thaiwong, Vilma Yuzbasiyan-Gurkan, Thomas Rülicke, Winfried Pickl, Michael Willmann, Peter Valent, M.D.

Blood (2010) 116 (21): 4936.

https://doi.org/10.1182/blood.V116.21.4936.4936

Published: 2010

Journal Articles

Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα.

Christian Baumgartner, MD, Karoline V. Gleixner, M.D., Alexander Gruze, Puchit Samorapoompichit, M.D., Harald Esterbauer, M.D, Winfried F. Pickl, M.D, Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 3559.

https://doi.org/10.1182/blood.V110.11.3559.3559

Published: 2007

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Veronika Ferenc, MD, Karoline V. Gleixner, M.D., Alexander Gruze, M.D., Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 3554.

https://doi.org/10.1182/blood.V110.11.3554.3554

Published: 2007

Journal Articles

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

Karoline V. Gleixner, MD, Matthias Mayerhofer, M.D., Uwe Rix, Ph.D., Gregor Hoermann, Alexander Gruze, Maria-Theresa Krauth, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Giulio Superti-Furga, Ph.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1541.

https://doi.org/10.1182/blood.V110.11.1541.1541

Published: 2007

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Karoline V. Gleixner, MD, Veronika Ferenc, M.D., Alexander Gruze, Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1046.

https://doi.org/10.1182/blood.V110.11.1046.1046

Published: 2007

NARROW

Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,

5-Azacytidine and Decitabine Induce Demethylation and Re-Expression of FAS (CD95) and Promote Apoptosis in Neoplastic Cells in Acute Myeloid Leukemia (AML),

Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML,

Ponatinib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis,

The Leukemic Stem Cell (LSC) in Ph + CML Is a CD34 + /CD38 − /Lin − Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release

The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML

Expression of the CAMPATH-1 Antigen (CD52) on CD34+/CD38- Progenitor Cells in Patients with 5q- MDS and in a Subset of AML

Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.

Identification of Novel Surface Markers and Targets In Neoplastic Stem Cells In AML and CML: a Flow-Gene-Flow Screen Approach.

Establishment of a Novel Canine Mastocytoma Cell Line, NI-1: a Model for Studying Resistance Against KIT Tyrosine Kinase Inhibitors In Canine Neoplastic Mast Cells

Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα.

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only